Latest Definium Therapeutics News & Updates

See the latest news and media coverage for Definium Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Definium Therapeutics

Psychedelic medicine company for brain health disorders

definiumtx.com

Headquarters: New York, United States
Founded year: 2019
Company type: Public company
Number of employees: 125–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Definium Therapeutics

In short: Definium Therapeutics rebranded from MindMed, reported positive Phase 3 depression trial results, and raised $805 million in gross proceeds.

Company announcements

July 1 Definium Therapeutics

Definium Therapeutics reports Phase 3 results for LSD in MDD

CEO Robert Barrow discusses positive Emerge results and the company's commitment to advancing mental health treatments

June 25 Definium Therapeutics

Definium Therapeutics announces closing of $805 million upsized public offering

The offering included full exercise of underwriters' option to purchase additional shares. Proceeds will fund R&D and potential commercialization.

June 24 Definium Therapeutics

Definium Therapeutics announces pricing of $700 million upsized public offering

The offering of 20,588,236 common shares at $34.00 per share is expected to close June 25, 2026.

June 22 Definium Therapeutics

Definium Therapeutics announces proposed public offering of $500 million common shares

The company plans to use proceeds for R&D, potential commercialization of DT120 ODT, and working capital.

Media coverage

Today Seeking Alpha

Definium outlines cash runway into 2030 as Voyage GAD Phase III top line results near (NASDAQ:DFTX)

Definium Therapeutics (DFTX) Q2 2026 earnings call: DT120 ODT Phase III GAD catalysts (Voyage Aug 10...

Yesterday Yahoo Finance

Definium Therapeutics Q2 Earnings Call Highlights

Definium Therapeutics (NASDAQ:DFTX) said it expects to report top-line results from its Phase III VOYAGE study of DT120 ODT in generalized anxiety...

July 27 GuruFocus

DFTX Initiates Coverage On Wells Fargo -- Rating Set to Overweig

On July 27, 2026, Wells Fargo initiated coverage on Definium Therapeutics (DFTX) with an Overweight...

July 24 GuruFocus

DFTX Reiterated by Piper Sandler -- Price Target Raised to $73.0

On July 24, 2026, Piper Sandler analyst David Amsellem reiterated his Overweight rating for Definium...

Never miss news about Definium Therapeutics

Track Definium Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Definium Therapeutics competitors & trending companies

Browse news for competitors to Definium Therapeutics and other trending companies.